Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322968 · ClinicalTrials.gov registry record · Phase 3
Ketamine Infusion for Comorbid PTSD and Chronic Pain
A Phase 3 study, sponsored by VA Ann Arbor Healthcare System.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT04322968 is a Phase 3 study that has completed, run by VA Ann Arbor Healthcare System. The registered enrollment target is 41 participants.
The verdict
NCT04322968, a Phase 3 study, has completed, sponsored by VA Ann Arbor Healthcare System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effectiveness of low dose IV ketamine infusion in the treatment of patients with PTSD and comorbid chronic pain. Hypothesis: A single ketamine infusion should be associated with significantly greater reduction in core PTSD symptom levels after the treatment and such an effect is not only due to its analgesic properties but also through unknown mechanism of action that maybe related to NMDA/AMPA receptor modulation.
Interventions
- DRUG A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2019-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322968
The ClinicalTrials.gov registry entry for NCT04322968 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Ann Arbor Healthcare System, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms. is the first listed.
NCT04322968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04322968 about?
NCT04322968 is a clinical study titled "Ketamine Infusion for Comorbid PTSD and Chronic Pain". The purpose of the study is to investigate the effectiveness of low dose IV ketamine infusion in the treatment of patients with PTSD and comorbid chronic pain. Hypothesis: A single ketamine infusion should be associated with significantly greater reduction in core PTSD symptom levels after the trea...
What is the current status of trial NCT04322968?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2018-01-09. Estimated completion is 2019-06-04.
What interventions are being tested in trial NCT04322968?
The interventions under investigation include: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms. (DRUG).
Who is sponsoring clinical trial NCT04322968?
This trial is sponsored by VA Ann Arbor Healthcare System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.